While ketogenic diets have been proposed to offer anti-inflammatory benefits in MS, the findings suggest the type of fat may ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type 1 diabetes, hepatitis ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage ...

Investing.com -- Contineum Therapeutics Inc (NASDAQ: CTNM) stock fell 8.4% after the clinical-stage biopharmaceutical company announced a delay in reporting topline data from its Phase 1b trial of ...

Birmingham has a very strong history of immunology research going back 30 years, and with one of the greatest concentrations of scientists and doctors in the world is well positioned to make a ...

US biotech fund BVF Parners has sold its stake in drug developer Syntara, thus exiting all of its ASX life sciences exposures ...

ARGX-119 in congenital myasthenic syndromes: Amsterdam, the Netherlands Tuesday, July 1, 2025, 18:00 Hrs [IST] argenx SE, a global immunolo ...

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduct ...